CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the company’s PurISTSM algorithmic test has received a ...

Tempus AI, Inc. (NASDAQ:TEM) ranks among the best AI stocks to buy according to analysts. On December 8, TD Cowen reaffirmed its Hold rating on Tempus AI, Inc. (NASDAQ:TEM), with an $88 price target.

July 9 (Reuters) - Wall Street brokerages started covering SoftBank Group-backed Tempus AI (TEM.O), opens new tab on a bullish note on Tuesday, betting that the company's AI-powered library of ...

Tempus AI stock is showing a mixed technical picture, with a moderately bearish trend and ongoing selling pressure, indicating potential downside risk. The stock, at $69.85, sits well below its ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the ...

Tempus AI has expanded its relationship with Personalis, investing $36 million in the oncology biotech and becoming the exclusive commercial partner for its test to detect minimal residual disease, or ...

Tempus AI’s TEM reimbursement showed modest sequential improvement in the third quarter of 2025, though average blended reimbursement per test continues to lag peers by a meaningful margin. The ...

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device ...

Investing.com - Stifel maintained its Hold rating and $65.00 price target on Tempus AI Inc (NASDAQ:TEM) following discussions with company management about business trends and key assumptions. The ...

Tempus is different thanks to its ability to layer additional similar patients’ information like imaging data and patient records on top of the test results, Bank of America Merrill Lynch analyst ...

Tempus AI has been publicly traded for only 16 months, and it has been nothing short of a market standout over that time. Compared to its IPO price of $37, Tempus shares were up by a whopping 155% on ...